Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of aprepitant injection for prevention of chemotherapy-induced nausea and vomiting
ChiCTR2300069353Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Henan Cancer Hospital. Primary endpoint: Complete response during overall treatment period (0–120 hours). Planned start Jan 2023; status: not yet recruiting.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2300069353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069353.